Keyword: Ablynx

Sanofi just won FDA approval for Cablivi, acquired in its $4.5 billion Ablynx deal and expected to peak at $500 million in sales.

Cablivi is the first Ablynx nanobody drug to win approval, and analysts have predicted peak sales of $500 million.

Analysts previously predicted Cablivi (caplacizumab) could be the standard of care for aTTP, with peak global sales at $500 million.

Sanofi's CFO search lasted two months and led the company to a financial executive from French automaker PSA Group.

Jérôme Contamine, Sanofi's CFO for nearly a decade, plans to step down later this year after a transition period.

Other bidders may have dropped out of an auction for Sanofi's European generics unit, but that doesn't mean it hasn't found a buyer.

Sanofi is out another potential buyer for its European generics business as India-based Torrent Pharma exited deal talks, according to a report.

Sanofi has narrowed down the field of potential buyers to drug companies from Brazil and India, plus several private equity funds, Reuters reports.

Let’s just say it hasn’t been a great week for Novo Nordisk.

Sanofi, which has been converting its biologics plant in Framingham, Massachusetts, to digital manufacturing, will again expand the facility.